RICHTER SYNDROME

This early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…

This study is testing a new combination of two oral drugs, duvelisib and venetoclax, for adults with chronic lymphocytic leukemia (CLL) or Richter's syndrome that has come back or stopped responding to prior treatment. The first part of the study aims to find a safe dose when the…

This study is testing a new three-drug combination to control B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see if adding a new immunotherapy drug (ALX148) to two existing drugs (rituximab and lenalidomide) helps patients whose cancer has returned or is newly d…

This study is testing whether combining three different drugs works better for people with chronic lymphocytic leukemia (CLL) or a more aggressive form called Richter transformation that has returned or hasn't responded to other treatments. The combination includes two immunother…

This early-stage study is testing a new four-drug combination for a very aggressive type of lymphoma that has returned or stopped responding to standard treatments. The goal is to see if combining an immunotherapy drug (atezolizumab) with two chemotherapy drugs and a targeted ant…

This is an early-stage study to find the safest dose of two cancer drugs, copanlisib and nivolumab, when given together. It is for adults with aggressive blood cancers that have transformed from slower-growing types, like Richter's syndrome. The main goal is to see how well patie…

This study aims to learn how a new immunotherapy drug called epcoritamab works against two types of blood cancer. Researchers will analyze small tissue samples from five invited patients before and during their treatment. The goal is to see how the drug affects cancer cells and t…